Code intelligence

FDA-NDA218275 reimbursement alerts

Policy changes, MAC LCD updates, and CMS guidance referencing code FDA-NDA218275.

Critical code risk

Signal breakdown

1 shown · 1 total in platform

Risk: Critical

Critical

100%

High

Routine

Low

New this month

alerts added in last 30 days

Effective soon

—

no upcoming deadlines

FDA Approval: ZEVTERA (CEFTOBIPROLE MEDOCARIL SODIUM) — Type 1 - New Molecular Entity

Policy FDA-NDA218275 · Infectious Disease

Critical

Zevtera (ceftobiprole medocaril sodium) is an intravenous antibiotic approved via NDA218275, administered as a reconstituted powder for IV infusion, placing it squarely in the Medicare Part B billing

View alert